Evolving treatments for advanced gastric cancer

Appraisal of the survival trend

Michela Roberto, Adriana Romiti, Concetta Elisa Onesti, Angelo Zullo, Rosa Falcone, Paolo Marchetti

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

ABSTRACT: Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.

Original languageEnglish
Pages (from-to)717-729
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2 2016

Fingerprint

Stomach Neoplasms
Survival
Drug Therapy
Esophagogastric Junction
Pharmaceutical Preparations
Immunotherapy
Stomach
Therapeutics
Biomarkers
Neoplasms
Clinical Studies

Keywords

  • Advanced gastric cancer
  • Chemotherapy
  • Immunotherapy
  • Metronomic chemotherapy
  • Target therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Roberto, M., Romiti, A., Onesti, C. E., Zullo, A., Falcone, R., & Marchetti, P. (2016). Evolving treatments for advanced gastric cancer: Appraisal of the survival trend. Expert Review of Anticancer Therapy, 16(7), 717-729. https://doi.org/10.1080/14737140.2016.1184979

Evolving treatments for advanced gastric cancer : Appraisal of the survival trend. / Roberto, Michela; Romiti, Adriana; Onesti, Concetta Elisa; Zullo, Angelo; Falcone, Rosa; Marchetti, Paolo.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 7, 02.07.2016, p. 717-729.

Research output: Contribution to journalReview article

Roberto, M, Romiti, A, Onesti, CE, Zullo, A, Falcone, R & Marchetti, P 2016, 'Evolving treatments for advanced gastric cancer: Appraisal of the survival trend', Expert Review of Anticancer Therapy, vol. 16, no. 7, pp. 717-729. https://doi.org/10.1080/14737140.2016.1184979
Roberto, Michela ; Romiti, Adriana ; Onesti, Concetta Elisa ; Zullo, Angelo ; Falcone, Rosa ; Marchetti, Paolo. / Evolving treatments for advanced gastric cancer : Appraisal of the survival trend. In: Expert Review of Anticancer Therapy. 2016 ; Vol. 16, No. 7. pp. 717-729.
@article{67fea0ab91fc4e9fa9c11dfb24178fd7,
title = "Evolving treatments for advanced gastric cancer: Appraisal of the survival trend",
abstract = "ABSTRACT: Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.",
keywords = "Advanced gastric cancer, Chemotherapy, Immunotherapy, Metronomic chemotherapy, Target therapy",
author = "Michela Roberto and Adriana Romiti and Onesti, {Concetta Elisa} and Angelo Zullo and Rosa Falcone and Paolo Marchetti",
year = "2016",
month = "7",
day = "2",
doi = "10.1080/14737140.2016.1184979",
language = "English",
volume = "16",
pages = "717--729",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Evolving treatments for advanced gastric cancer

T2 - Appraisal of the survival trend

AU - Roberto, Michela

AU - Romiti, Adriana

AU - Onesti, Concetta Elisa

AU - Zullo, Angelo

AU - Falcone, Rosa

AU - Marchetti, Paolo

PY - 2016/7/2

Y1 - 2016/7/2

N2 - ABSTRACT: Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.

AB - ABSTRACT: Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.

KW - Advanced gastric cancer

KW - Chemotherapy

KW - Immunotherapy

KW - Metronomic chemotherapy

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=84976571183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976571183&partnerID=8YFLogxK

U2 - 10.1080/14737140.2016.1184979

DO - 10.1080/14737140.2016.1184979

M3 - Review article

VL - 16

SP - 717

EP - 729

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 7

ER -